Fig. 5. Antitumor effects of recombinant Annexin A5-E7 fusion protein.

C57BL/6 mice were injected with 2 × 10⁵ TC-1 cells/mouse subcutaneously on day 0. Mice were then treated intraperitoneally with 5 mg/kg Cisplatin on days 12 and 15, intravenously with 200jig/mice of Annexin A5-E7 fusion protein, 200jig/mice of Annexin A5 proteins, and/or 3.5jig/mice of E7 long peptide on days 13, 14, 16, and 17. The treatment groups are as follows: opened triangle—PBS only; closed triangle—cisplatin only; opened square—E7 peptide only; closed square—cisplatin and E7 peptide; opened sphere—Annexin A5 only; closed sphere—cisplatin and Annexin A5; opened circle—Annexin A5-E7peptide only; closed circle—cisplatin and Annexin A5-E7 peptide. a Schematic diagram. b Line graph depicting TC-1 tumor growth in different treatment groups over time (n = 10). P-values were determined by one-way ANOVA and Turkey’s test. c Kaplan–Meier survival analysis of TC-1 tumor-bearing mice in different treatment groups (n = 10), and the overall P-value was calculated by the log-rank test. d, e On days 18 and 23, tumor tissues and spleens of TC-1 tumor-bearing mice in different treatment groups were harvested and analyzed for CD8+IFN-γ+ or CD8+E7tetramer+ T cells by flow cytometry analysis, respectively. d Representative flow cytometry analysis and bar graph depicting the abundance of CD8+E7tetramer+ T cells in splenocytes of TC-1 tumor-bearing mice in different treatment groups (n = 3). e Representative flow cytometry analysis and bar graph depicting the abundance of CD8+IFN-γ+tumor-infiltrating T cells in TC-1 tumor-bearing mice in different treatment groups (n = 3). The error bars indicate mean ± SD. For (d, e), P-values were analyzed by Student’s t test. The results are representative of one of three independent experiments. Source data are provided as a Source Data file.